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Meta-analysis of Genome-wide Association Studies
for Neuroticism, and the Polygenic Association
WithMajor Depressive Disorder
Genetics of Personality Consortium
IMPORTANCE Neuroticism is a pervasive risk factor for psychiatric conditions. It genetically
overlaps with major depressive disorder (MDD) and is therefore an important phenotype for
psychiatric genetics. The Genetics of Personality Consortium has created a resource for
genome-wide association analyses of personality traits in more than 63 000 participants
(including MDD cases).
OBJECTIVES To identify genetic variants associated with neuroticism by performing a
meta-analysis of genome-wide association results based on 1000 Genomes imputation; to
evaluate whether common genetic variants as assessed by single-nucleotide polymorphisms
(SNPs) explain variation in neuroticism by estimating SNP-based heritability; and to examine
whether SNPs that predict neuroticism also predict MDD.
DESIGN, SETTING, AND PARTICIPANTS Genome-wide associationmeta-analysis of 30 cohorts
with genome-wide genotype, personality, andMDD data from the Genetics of Personality
Consortium. The study included 63 661 participants from 29 discovery cohorts and 9786
participants from a replication cohort. Participants came from Europe, the United States, or
Australia. Analyses were conducted between 2012 and 2014.
MAIN OUTCOMES ANDMEASURES Neuroticism scores harmonized across all 29 discovery
cohorts by item response theory analysis, and clinical MDD case-control status in 2 of the
cohorts.
RESULTS A genome-wide significant SNPwas found on 3p14 inMAGI1 (rs35855737;
P = 9.26 × 10−9 in the discovery meta-analysis). This association was not replicated (P = .32),
but the SNPwas still genome-wide significant in themeta-analysis of all 30 cohorts
(P = 2.38 × 10−8). Common genetic variants explain 15% of the variance in neuroticism.
Polygenic scores based on themeta-analysis of neuroticism in 27 cohorts significantly
predicted neuroticism (1.09 × 10−12 < P < .05) andMDD (4.02 × 10−9 < P < .05) in the 2 other
cohorts.
CONCLUSIONS AND RELEVANCE This study identifies a novel locus for neuroticism. The variant
is located in a known gene that has been associated with bipolar disorder and schizophrenia
in previous studies. In addition, the study shows that neuroticism is influenced bymany
genetic variants of small effect that are either common or tagged by common variants. These
genetic variants also influenceMDD. Future studies should confirm the role of theMAGI1
locus for neuroticism and further investigate the association ofMAGI1 and the polygenic
association to a range of other psychiatric disorders that are phenotypically correlated with
neuroticism.
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D imensions of personality have been linkedwith the li-ability to have psychiatric illness.1 Perhaps the stron-gest link betweenpersonality andpsychiatric illness is
the association of neuroticismwithmajor depressive disorder
(MDD).2-5 Neuroticism is also associated with other psychiat-
ricdisorders thatentail emotionaldysregulation, includingper-
sonality, substance use, and anxiety disorders.2,6-8 Further-
more,neuroticismisassociatedwithneurologicaldiseasessuch
asmigraine andAlzheimer disease.9,10 Hence, neuroticism is a
psychological riskfactorofprofoundpublichealthsignificance.11
Neuroticismreferstothetendencytoexperiencediverseand
relatively more intense negative emotions. Neuroticism and
similar traits such as harm avoidance and negative emotion-
ality share an affective underpinning12 and are found in all
main theories of personality.13-24 Twin studies of neuroti-
cism, harm avoidance, or negative emotionality generally
find that between 40% and 60% of the trait variance is
explained by genomic variation,3,25-28 and it has been found
that there are no large age-by-genotype or sex-by-genotype
effects, modest assortative mating, and large genetic and
phenotypic stability across the life span.28-31 These findings
and the fact that neuroticism is strongly related to MDD7,32-35
make neuroticism an important phenotype for psychiatric
genetic studies.
Genome-wide association (GWA) studies require large
sample sizes to have sufficient statistical power, which is of-
ten achieved by aggregating results in multiple cohorts in a
meta-analysis.However, this requiresameasurementscale that
is comparable across cohorts.We recently showed forneuroti-
cism and extraversion howdifferent personality instruments
could be linked through item response theory analysis to as-
sess the same underlying constructs.36 Personality item data
were harmonized inmore than 160 000participants from the
Genetics of Personality Consortium. A meta-analysis of data
frommore than 29 000 twin pairs from 6 of the participating
cohorts showed that the heritability of the harmonized neu-
roticism scores was 48%.36 This estimate was based on twin
correlations that ranged between 0.39 and 0.53 for monozy-
gotic twin pairs and between 0.11 and 0.26 for dizygotic twin
pairs across cohorts and sexes. The opposite-sex twin corre-
lations were not significantly lower than the same-sex dizy-
gotic twin correlations, illustrating that the same genetic fac-
tors influence neuroticism in men and women.
Gene-finding studies for MDD and neuroticism-like per-
sonality traitshavehad limitedsuccess todate.Therehavebeen
2 meta-analytic GWA studies for personality traits, including
neuroticismandharmavoidance.The sample sizeswere small
by current standards (N = 11 590 in the studyby Service et al37
and N = 17 375 in the study by de Moor et al38) and single-
nucleotide polymorphisms (SNPs) were imputed using
HAPMAPas a reference. The largestGWA39-41 studies forMDD
are those from the Psychiatric Genomics Consortium, with
9240 MDD cases and 9519 controls in the discovery phase of
the study and 6783MDD cases and 50 695 controls in the rep-
licationphase, and imputationbasedonHAPMAP.These stud-
ies did not detect genome-wide significant SNPs.42
To assess whether gene-finding efforts are likely to have
success, techniques have been developed that test whether
common variants tagged by genome-wide SNP arrays con-
tribute to variation in the phenotype.43 Two such studies for
neuroticism found effects of common SNPs, explaining
about 6% of the phenotypic variance, and another study for
MDD found that common SNPs explain 28% to 32% of the
phenotypic variance.44-46 In young children, genome-wide
SNPs explained 13% to 43% of the variance in internalizing
problems.47
Herein,we report results of the largestGWAstudy forneu-
roticismso far, to our knowledge, conducted in63 661 partici-
pants from 29 cohorts. A replication cohort of 9786 partici-
pants was also included. Imputation was performed against
the 1000Genomes referencepanel. Themain aimof the study
was to identify genetic variants for neuroticism by perform-
ing a meta-analysis of GWA results. Additional aims were to
estimate SNP-based heritability in 2 of the largest cohorts to
establish that the sets of SNPs contain information to detect
geneticvariantsandto testwhether thesevariantspredictMDD
status in a large cohort of clinically assessed MDD cases and
screened controls.
Methods
Cohorts
Themeta-analysis included 29 discovery cohorts, with 21 co-
horts from Europe, 6 from the United States, and 2 fromAus-
tralia. The analyses were conducted between 2012 and 2014.
All participants were of European descent. The total sample
size was 63 661 for the GWA meta-analysis. The Generation
Scotland: Scottish FamilyHealth Study cohort (n = 9786)was
included for replication of GWA top results. For more infor-
mation on each cohort, see eAppendix 1 and eTable 1 in the
Supplement.Approvalby local institutional reviewboardswas
obtained inall studiesand informedconsentwasobtainedfrom
all participants.
Phenotyping
After harmonizing all item data on neuroticism from mul-
tiple instruments, comparable neuroticism scores were ob-
tained for all cohorts.36These scoreswereestimated for all par-
ticipantsafter conducting itemresponse theoryanalysison the
available item data for neuroticism from theNEO Personality
Inventory, Eysenck Personality Questionnaire, and Interna-
tional Personality Item Pool inventory, all item data for harm
avoidance fromCloninger’s Tridimensional PersonalityQues-
tionnaire, andall itemdata for negative emotionality fromthe
Multidimensional Personality Questionnaire (eAppendix 1 in
the Supplement). For theGeneration Scotland cohort, pheno-
typeswere summedscores on theneuroticismscale of theEy-
senck Personality Questionnaire Revised Short Form.
Genotyping and Imputation
An overview of SNP genotyping, quality control, and imputa-
tion is given in eTable 2 in the Supplement. Quality control of
genotype data was performed in each study independently,
usingcomparablebut study-specific criteria.Basicquality con-
trol steps included checks for European ancestry, sex incon-
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sistencies, mendelian errors, and high genome-wide homo-
zygosity. Checks for relatedness were carried out in those
samples that aimed to include unrelated individuals only.
Genotype data were further checked based on Hardy-
Weinberg equilibrium,minor allele frequencies (MAFs), SNP,
and sample call rates. Genotype datawere imputed using the
1000Genomesphase1version3 (build37,hg19) referencepanel
with standard software packages such as IMPUTE, MACH, or
Minimac (eTable 2 in the Supplement).
Statistical Analysis
GWAAnalyses in Each Cohort
TheGWAanalyseswere conducted in each cohort using linear
regression (additivemodel,withsexandageascovariates)with
the aim to identify single common genetic variants that influ-
enceneuroticisminbothmenandwomenofdifferentages.De-
pending on the characteristics of the cohort, additional covar-
iates such as principal components were added. Different
software packages were used to run the association analysis
(eTable2 in theSupplement).Uncertaintyof the imputedgeno-
typeswas taken intoaccount. In thosecohorts that includedre-
lated individuals, the dependency among participantswas ac-
counted for. Locations of SNPs are reported on build 37 (hg19).
Meta-analysis of GWAResults Across Cohorts
A meta-analysis of the GWA results of the discovery cohorts
was conducted using the weighted inverse variance method
in METAL (http://csg.sph.umich.edu/abecasis/Metal/). This
is a fixed-effects model in which effect sizes (β) are
weighted by the inverse of their variance and then summed
over cohorts. This model is appropriate if phenotypes are on
a similar scale, which was the case for the harmonized neu-
roticism scores. Poorly imputed SNPs (r2 < 0.30 or proper-
_info < 0.40) and SNPs with low MAF (MAF <[5/n], which
corresponds to fewer than 5 estimated individuals in the
least frequent genotype group, under the assumption of
Hardy-Weinberg equilibrium) were excluded, resulting in a
total number of 1.1 million to 6.6 million SNPs across
cohorts. The number of unique SNPs available for meta-
analysis was 7 480 565. For 530 951 SNPs, association results
were available in 1 cohort only and were discarded, leading
to a final 6 949 614 SNPs for which results are reported.
Genomic control inflation factors (λ) and Manhattan and
quantile-quantile plots per cohort are provided in eTable 3,
eFigure 1, and eFigure 2 in the Supplement. The SNPs with
P = 5 × 10−8 or smaller were considered genome-wide sig-
nificant. In the Generation Scotland cohort, all SNPs with
P < 1 × 10−5 were tested for replication. For these SNPs, a
meta-analysis of all 30 cohorts was conducted. Because sum
scores were available for neuroticism in the Generation
Scotland cohort, this meta-analysis was based on combining
P values, taking into account the direction of effect and
weighting by sample size, rather than combining effect
sizes.
Figure 1. Region Plot for Genome-wide Significant Single-Nucleotide Polymorphism (SNP) rs35855737 inMAGI1 on Chromosome 3 for Neuroticism
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Variance Explained by Common SNPs
In 2 large cohorts included in the meta-analysis, the Nether-
lands Twin Register (NTR; n = 3599 unrelated individuals) co-
hortandtheQIMRBerghoferMedicalResearchInstitute (QIMR;
n = 3369) adult cohort, genomic-relatedness-matrix restricted
maximum likelihood analysis in the Genome-wide Complex
TraitAnalysis (GCTA) softwarewasapplied toestimate thepro-
portionofvariance inneuroticismthatcanbeexplainedbycom-
mon SNPs.43,48 The GCTA analysis was based on best-guess
genotypes obtained in PLINK using a threshold of a maxi-
mum genotype probability > 0.70, and additionally filtering
on r2 > 0.80. Next, in estimating the genetic relationship
matrix in the GCTA software, SNPs with MAF < 0.05 were
excluded. The additive genetic relationship matrix for all
individuals in the data sets estimated based on SNPs was
used to estimate the proportion of phenotypic variance due
to additive genetic variance. Sex, age, and population-
specific principal components were included as covariates.
Polygenic Risk Score Analysis
Polygenic risk score (PGS) analyseswere conducted to test the
predictive power of themeta-analysis results for neuroticism
itself and for MDD. The PGSs were computed in the NTR co-
hort and the Netherlands Study of Depression and Anxiety
(NESDA) cohort49 and were based on the meta-analysis re-
sults excluding the NTR and NESDA cohorts, further referred
to as the PGS discovery set. The PGSs were calculated for all
individuals of theNTR andNESDA target set by taking a set of
most significant SNPs from the analysis in the PGS discovery
set, multiplying the individual’s genotypic score (0, 1, or 2
for genotyped SNPs, or any value between 0-2 for imputed
SNPs) by theeffect sizeof aparticular SNP (unstandardized re-
gression coefficient based on the meta-analysis), and sum-
ming this over SNPs. The PGSs were calculated for 6 P value
thresholds (P < 1 × 10−5,P < 1 × 10−4,P < 1 × 10−3,P < .01,P < .05
and P < .50). Next, linear regression was conducted to pre-
dict neuroticism from the PGSs in 8648NTRparticipants. Lo-
gistic regressionwas conducted topredictMDDstatus in 1859
unrelatedMDDcasesand2391unrelatedcontrols fromtheNTR
and NESDA cohorts. The MDD case-control status was de-
fined as a lifetime DSM-IV diagnosis using the Composite In-
ternationalDiagnostic Interview.Age, sex,and9principal com-
ponents were included as covariates. eAppendix 1 in the
Supplement includes more details on selection of partici-
pants in these cohorts and analysis.
Results
Meta-analysis of GWAResults for Neuroticism
Meta-analysis of GWA results across the 29 cohorts revealed 1
genome-widesignificantSNP(rs35855737;P = 9.26 × 10−9).The
SNP is located on 3p14 in an intron of MAGI1 (Figure 1). The
pooled regression effect was −0.04 with the minor allele C
codedas theeffectallele (Figure2). Imputationqualitywasvery
high (r2 orproper_info > 0.94) in all cohorts, except in theEras-
musRucphenFamily (ERF) cohort (r2 = 0.63). TheMAFof the
SNP ranged from 0.13 to 0.22 across cohorts with imputation
qualitygreater than0.94andshowedamean(SD)of0.18 (0.02),
which corresponds to the MAF for this SNP in the 1000 Ge-
nomes reference set. The MAF in the ERF cohort was 0.07.
Eleven other SNPs in MAGI1 showed suggestive genome-
wide significance (P < 1 × 10−5); all SNPs were intronic; 1 SNP
was in very high linkage disequilibrium with rs35855737
(rs1404544; r2 > 0.80;P = 8.59 × 10−6); and3SNPswere inhigh
linkagedisequilibriumwith rs35855737 (rs1524970, rs1880522,
and rs6799284; r2 > 0.60; 3.64 × 10−6 < P < 8.54 × 10−7). The
Figure 2. Forest Plot for Genome-wide Significant Single-Nucleotide
Polymorphism rs35855737 inMAGI1 on Chromosome 3 for Neuroticism
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Manhattan and quantile-quantile plots are shown in Figure 3
andFigure 4. A listwith all 127 suggestively genome-wide sig-
nificant SNPs is provided in eTable 4 in the Supplement (full
results of the meta-analysis can be downloaded from http:
//www.tweelingenregister.org/GPC).
Results of the follow-up analysis for all SNPs with
P < 1 × 10−5 in theGeneration Scotland cohort aredisplayed in
eTable 4 in the Supplement. The SNP rs35855737 is not signifi-
cantly associated with neuroticism in the Generation Scot-
landcohort,but thedirectionof theeffect is thesame(β = −0.02
for effect allele C;P = .32). Ameta-analysis of the results from
all 30cohorts shows that rs35855737 remainsgenome-widesig-
nificant (β = −0.04; P = 2.38 × 10−8).
Variance in Neuroticism Explained by Common SNPs
In the NTR cohort, 14.7% of the variance in neuroticism was
explainedbyall SNPs (P = .02;95%CI,0.002-0.29). In theQIMR
cohort, 15.7% of the variance was explained by SNPs (P = .18;
95% CI, 0-0.47).
Polygenic Risk Score Analysis for Neuroticism andMDD
The results of the polygenic risk score analyses are presented
in Figure 5. In the NTR cohort, polygenic risk scores are sig-
nificantly (P < .05) associated with neuroticism when poly-
genic scores are based on SNP sets with thresholds of
Figure 4. Quantile-Quantile Plots forMeta-analysis Results for
Neuroticism in 29 Discovery Cohorts
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Figure 5. Results of Polygenic Risk Score Analyses PredictingMajor
Depressive Disorder (MDD) and Neuroticism Based on Neuroticism
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Figure 3. Manhattan Plot forMeta-analysis Results for Neuroticism in 29 Discovery Cohorts
8
6
4
2
0
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 19 2118 20 22
−L
og
10
(P
 V
al
ue
)
Chromosome
Blue line indicates the threshold of suggestive genome-wide significance P < 1 × 10−5 (or the log thereof); red line, threshold of genome-wide significance
P < 5.0 × 10−8 (or the log thereof).
Research Original Investigation Neuroticism and Polygenic AssociationWith Major Depressive Disorder
646 JAMAPsychiatry July 2015 Volume 72, Number 7 (Reprinted) jamapsychiatry.com
Downloaded From: http://archpsyc.jamanetwork.com/ by a UQ Library User  on 10/12/2015
Copyright 2015 American Medical Association. All rights reserved.
P = 1 × 10−3 and lower. The most significant result was found
for theSNPsetwitha thresholdP = .50,withanexplainedvari-
anceof0.66%andP = 1.09 × 10−12 in the linear regressionanaly-
sis. In the combined NTR and NESDA cohorts, polygenic risk
scores are significantly (P < .05) associatedwithMDD for SNP
sets with thresholds of P = .01 and P = .05, with higher neu-
roticism predicting larger risk for MDD. The most significant
result was found for the SNP set with a threshold of P = .05,
with an explainedvariance of 1.05%andP = 4.02 × 10−9 in the
logistic regression analysis.
Discussion
The meta-analysis of GWA results for neuroticism showed a
genome-wide significant SNP on 3p14 in an intron of MAGI1.
This gene is expressed in neuronal tissue, in particular the
hippocampus, and is found at the synaptic plasma
membrane.50 Also, MAGI1 acts as a scaffolding protein in the
neurite growth factor receptor-mediated signaling pathway.51
Interestingly, MAGI1 has previously been implicated in bipo-
lar disorder, schizophrenia, and episodicity in MDD,52-54 dis-
orders that in part share their genetic etiology.55 A genome-
wide linkage scan for early-onset bipolar disorder type 1
revealed genome-wide significant linkage in the 3p14 region
where MAGI1 is located.54 A study of copy number variants
found deletions and duplications in MAGI1 to be associated
with bipolar disorder and schizophrenia.52 Further, a sugges-
tive association (P = 5.1 × 10−7) of an SNP in MAGI1 with epi-
sodicity in MDD was found in a GWA study. Episodicity is a
feature of MDD that shows increased risk to shifting to bipo-
lar disorder.53
The SNP-based genetic similarity across individuals ac-
counted for approximately 15% of the variance in neuroti-
cism. This estimate is larger than those in earlier reports, of
about6%.44,46Heritabilityestimates fromtwinstudiesareusu-
ally larger and range between 40% and 55%.36
Polygenic risk scores basedon theGWAmeta-analysis sig-
nificantly predictedMDD status in a large independent target
set consisting of MDD cases and screened controls. The poly-
genic scores for neuroticism reassuringly also predicted neu-
roticismincontrols forMDDof this sameindependentset.Neu-
roticism and MDD were explained about equally well by
neuroticism polygenic scores (up to 1.05% explained vari-
ance). These findings are consistentwithprevious reports that
studied the prediction of MDD and bipolar disorder based on
polygenic scores derived from Big Five neuroticism GWA
results.56,57
This study demonstrates that increasing the number of
participants and SNPs in a meta-analysis was successful in
identifying a novel locus for neuroticism. As expected, the
effect size of the identified SNP is very small (pooled regres-
sion coefficient of −0.04 for the harmonized score with a
variance of approximately 1). Together with our findings of
an SNP-based heritability of approximately 15% and an
increase in explained variance in the polygenic risk score
analysis when polygenic scores are based on larger sets of
SNPs, this suggests that neuroticism is highly polygenic.
Our results further indicate that the heritability of
neuroticism likely consists not only of common SNPs with
small effects. Rare variants, repeat polymorphisms,
and indels may also influence neuroticism, possibly in
gene-by-gene interactions (epistasis). As a consequence, to
further our understanding of the genetic and molecular
basis of neuroticism (and associated psychiatric disorders),
different routes need to be taken in future studies. One
route would be to increase the number of participants and
SNPs to further identify common variants. This route was
shown to be very successful for schizophrenia.58 Also, the
study of variants other than common SNPs should be pur-
sued. Alternative routes could include pathway analyses
and genetic studies that are informed by results from the
animal literature on basic emotions such as fear, sadness,
and anger.59-62
This study more than tripled the sample size compared
with thepreviouslypublishedmeta-analysis onpersonality,38
providing a substantial increase in power to detect variants.
The power to detect variants that explain 0.23% of the vari-
ance (corresponding to the effect size for themost significant
SNP in the previous meta-analysis38) increased from 84% to
100%. Inaddition,withasamplesizeof63 661 individuals there
is 80% power to detect variants that explain at least 0.063%
of the variance in neuroticism, compared with 1.6% power
given the 17 375 participants who were included in the previ-
ous meta-analysis.38 The large increase in sample size was
possible because an item response theory approach enabled
harmonization of personality data obtained from different
personality questionnaires, which may serve as an example
for gene-finding studies for other psychological, cognitive,
and psychiatric traits where harmonization is required to
increase sample size (eg, symptoms of depression or
attention-deficit/hyperactivity disorder measured by differ-
ent questionnaires).
Conclusions
The results for neuroticism were predictive for MDD. Future
analyses may focus on whether the MAGI1 locus and poly-
genic variance for neuroticism are also associated with psy-
chiatricdisorders that arephenotypically associatedwithneu-
roticism, such as borderline personality disorder, bipolar
disorder, schizophrenia, attention-deficit/hyperactivity dis-
order, and substanceusedisorders. This could be achievedby
combining data from the Genetics of Personality Consortium
with those available within the Psychiatric Genomics
Consortium63 and the Social Science Genetic Association
Consortium.64 Novelmethodswill be needed to test whether
neuroticism represents a causal risk factor forMDDandother
disorders,whether reversecausality is alsopresent,orwhether
the genetic association between neuroticism and psychiatric
disorders reflects an underlying common liability.55,65-67 It is
expected that such studieswill increase our understanding of
the role that emotional instability plays in the occurrence and
course of psychiatric disorders and other important health
outcomes.
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